M

Molecular Partners AG
D

MOLN

8.17000
USD
-0.41
(-4.78%)
مغلق
حجم التداول
160
الربح لكل سهم
0
العائد الربحي
0
P/E
-3
حجم السوق
188,874,071
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CHKP
    -1.570
    (-0.86%)
    181.910 USD
    CRWD
    -7.780
    (-3.35%)
    224.170 USD
    FTNT
    -0.790
    (-1.36%)
    57.230 USD
    N
    NET
    -3.130
    (-4.04%)
    74.380 USD
    O
    OKTA
    -2.465
    (-2.63%)
    91.415 USD
    PANW
    -9.11
    (-2.81%)
    315.55 USD
    P
    PFPT
    0
    (0%)
    0.000000 USD
    S
    SPLK
    0
    (0%)
    0.000000 USD
    V
    VMW
    0
    (0%)
    0.000000 USD
    Z
    ZS
    -4.980
    (-2.78%)
    174.400 USD
الأخبار
المقالات

العنوان: Molecular Partners AG

القطاع: Healthcare
الصناعة: Biotechnology
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.